Predict your next investment

HEALTHCARE | Drug Development
phasebio.com

See what CB Insights has to offer

Founded Year

2002

Stage

IPO | IPO

Total Raised

$144.94M

Date of IPO

10/18/2018

Market Cap

0.11B

Stock Price

2.14

About PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals (PHAS) is a clinical-stage biopharmaceutical company developing drugs to treat diabetes and cardiovascular dysfunction in patients suffering from rare diseases. The Company's discovery platform technology uses recombinant ELP biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The resulting compounds are tuned for a specific rate of absorption, thereby increasing efficacy and reducing side effects.

PhaseBio Pharmaceuticals Headquarter Location

1 Great Valley Parkway Suite 30

Malvern, Pennsylvania, 19355,

United States

610-981-6500

Latest PhaseBio Pharmaceuticals News

PhaseBio suspends Phase IIb pulmonary arterial hypertension therapy trial

Dec 22, 2021

PhaseBio Pharmaceuticals has voluntarily stopped the Phase IIb clinical trial of its new therapy, pemziviptadil (PB1046) to treat pulmonary arterial...Read More... The post PhaseBio suspends Phase IIb pulmonary arterial hypertension therapy trial  appeared first on Clinical Trials Arena.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing PhaseBio Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

PhaseBio Pharmaceuticals is included in 2 Expert Collections, including Diabetes.

D

Diabetes

1,750 items

B

Biopharma Tech

818 items

PhaseBio Pharmaceuticals Patents

PhaseBio Pharmaceuticals has filed 25 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Adrenal gland disorders
  • Antiandrogens
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/17/2020

10/5/2021

Prodrugs, Pregnanes, Antiandrogens, Transcription factors, Hepatotoxins

Grant

Application Date

1/17/2020

Grant Date

10/5/2021

Title

Related Topics

Prodrugs, Pregnanes, Antiandrogens, Transcription factors, Hepatotoxins

Status

Grant

PhaseBio Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

PhaseBio Pharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.